Soltamox 10mg/5ml Oral Solution
Soltamox 10mg/5ml Oral Solution
Each 5ml dose of oral solution contains tamoxifen 10mg (as tamoxifen citrate)
Excipients with known effect:
Ethanol - 750mg per 5 ml
Sorbitol solution (non-crystallising) (E420) - 1g per 5ml For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM Oral Solution
A clear colourless liquid
- Adjuvant treatment of oestrogen-receptor positive early breast cancer
- Treatment of oestrogen-receptor positive locally advanced or metastatic breast cancer
Adjuvant treatment of breast cancer, Adults (including elderly):
The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established.
Treatment of locally advanced or metastatic breast cancer:
The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.
Paediatric Population Children: Not applicable.
Method of Administration For oral use.
Pregnancy and lactation
Hypersensitivity to tamoxifen or to any of the excipients listed in section 6.1 Concurrent anastrozole therapy (see section 4.5)
Premenopausal patients must be carefully examined before treatment to exclude pregnancy.
Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy.
A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.
Menstruation is suppressed in a proportion of premenopausal women receiving tamoxifen for the treatment of breast cancer.
Any patients who have received tamoxifen therapy and have reported abnormal vaginal bleeding or patients presenting with menstrual irregularities, vaginal discharge and pelvic pressure or pain should undergo prompt investigation due to the increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours) which has been reported in association with tamoxifen treatment. The underlying mechanism is unknown, but may be related to the oestrogenic-like effect of tamoxifen.
Before initiating tamoxifen a complete personal history should be taken. Physical examination (including pelvic examination) should be guided by the patients past medical history and by the ‘contraindications’ and ‘special warnings and precautions for use’ warnings for use for tamoxifen. During treatment periodic check-ups including gynaecological examination focussing on endometrial changes are recommended of a frequency and nature adapted to the individual woman and modified according to her clinical needs.
When starting tamoxifen therapy the patient should undergo an ophthalmological examination. If visual changes (cataracts and retinopathy) occur while on tamoxifen therapy it is urgent that an ophthalmological investigation be performed, because some of such changes may resolve after cessation of treatment if recognised at an early stage.
In cases of severe thrombocytopenia, leucocytopenia or hypercalcaemia, individual risk-benefit assessment and thorough medical supervision are necessary.
• A 2-3-fold increase in the risk for VTE has been demonstrated in healthy tamoxifen-treated women (see section 4.8).
• Caution is advised regarding use of tamoxifen in patients who screen positive for thrombophilic factors; occasionally concomitant prophylactic anticoagulation may be justified (see section 4.5).
•VTE risk is further increased by severe obesity, increasing age and concomitant chemotherapy (see section 4.5). Long-term anti-coagulant prophylaxis may be justified for some patients with breast cancer who have multiple risk factors for VTE.
• Surgery and immobility: Tamoxifen treatment should only be stopped if the risk of tamoxifen-induced thrombosis clearly outweighs the risks associated with interrupting treatment. All patients should receive appropriate thrombosis prophylactic measures.
• Patients should be advised to seek immediate medical attention if they become aware of any symptoms of VTE; in such cases, tamoxifen therapy should be stopped and appropriate anti-thrombosis measures initiated.
• In the above all cases, the risks and benefits to the patient of tamoxifen therapy must be carefully considered.
The blood count including thrombocytes, liver function test and serum calcium should be controlled regularly.
Assessment of triglycerides in serum may be advisable because in most published cases of severe hypertriglyceridemia dyslipoproteinemia was the underlying disorder.
In the literature it has been shown that CYP2D6 poor metabolisers have a lowered plasma level of endoxifen, one of the most important active metabolites of tamoxifen (see section 5.2).
Concomitant medications that inhibit (CYPD2D6 may lead to reduced concentrations of the active metabolite endoxifen. Therefore, potent inhibitors of CYP2D6 (e.g. paroxetine, fluoxetine, quinidine, cinacalcet or bupropion) should whenever possible be avoided during tamoxifen treatment (see section
4.5 and 5.2).
Clinical trial data shows an increase in the incidence of depression in patients with breast cancer treated with tamoxifen. It is not clear whether this is related to tamoxifen treatment or to other factors (cancer diagnosis, surgery, chemotherapy, radiotherapy etc.). Clinicians supervising tamoxifen treatment should be aware of this increased incidence and screen patients for depression.
Tamoxifen is not intended for use in children.
This product contains 19% v/v ethanol, i.e. 750mg per dose equivalent to 19ml of beer or 8ml of wine per dose. It is harmful for those suffering from alcoholism. It should be taken into account in high-risk groups such as patients with liver disease or epilepsy. It may modify or increase the effect of other medicines.
This product contains glycerol which may cause headache, stomach upset and diarrhoea.
This product also contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
When used in combination with tamoxifen solution a significant increase in anticoagulant effect may occur. In the case of concomitant treatment particularly during the initial phase thorough monitoring of the coagulation status is mandatory.
Thrombocyte aggregation inhibitors:
In order to avoid bleeding during a possible thrombocytopenic interval thrombocyte aggregation inhibitors should not be combined with tamoxifen.
When used in combination with tamoxifen solution there is increased risk of thromboembolic events occurring (see also Sections 4.4 and 4.8). Because of this increase in risk of VTE, thrombosis prophylaxis should be considered for these patients for the period of concomitant chemotherapy. Tamoxifen and its metabolites have been found to be inhibitors of hepatic cytochrome p-450 mixed function oxidases. The effect of tamoxifen on metabolism and excretion of other antineoplastic drugs, such as cyclophosphamide and other drugs that require mixed function oxidases of activation, is not known.
The use of tamoxifen in combination with anastrozole as adjuvant therapy has not shown improved efficacy compared with tamoxifen alone.
Tamoxifen increases the dopaminergic effect of bromocriptine.
Hormone preparations, particularly oestrogens (e.g. oral contraceptives) should not be combined with tamoxifen because a mutual decrease in effect is possible.
As tamoxifen is metabolised by cytochrome P450 34A, care is required when co-administered with drugs known to induce this enzyme, such as rifampicin, as tamoxifen levels may be reduced. The clinical relevance of this reduction is unknown.
Plasma concentrations of tamoxifen may be increased by concomitant treatment with CYP3A4 inhibitors.
Pharmacokinetic interaction with CYP2D6 inhibitors, showing a reduction in plasma level of an active tamoxifen metabolite, 4-hydroxy-N-desmethyltamoxifen (endoxifen), has been reported in the literature. The relevance of this to clinical practice is not known.
Pharmacokinetic interaction with CYP2D6 inhibitors, showing a 65-75% reduction in plasma levels of one of the more active forms of the drug, i.e. endoxifen, has been reported in the literature. Reduced efficacy of tamoxifen has been reported with concomitant usage of some SSRI antidepressants (e.g. paroxetine) in some studies. As a reduced effect of tamoxifen cannot be excluded, co-administration with potent CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, quinidine, cinacalcet or bupropion) should whenever possible be avoided (see section 4.4 and 5.2).
There are only data from a small number of women who have been exposed to tamoxifen during pregnancy. Although no causal relationship has been established, only a small number of spontaneous abortions, birth defects and foetal deaths in women treated with tamoxifen during pregnancy have been reported.
Animal studies have shown reproduction toxicity (see section 5.3). Although the clinical relevance of the observed preclinical effects is unknown, some of them, especially vaginal adenosis, are similar to those seen in young women who were exposed to DES in utero and who have a 1 in 1000 risk of developing clear cell carcinoma of the vagina or cervix. Such exposure has not been reported to cause subsequent vaginal adenosis or clear cell carcinoma of the vagina or cervix in the small number of young women known to have been exposed in utero to tamoxifen.
Since the use of tamoxifen during pregnancy is contraindicated, women should be advised not to become pregnant whilst taking tamoxifen and within two months after stopping tamoxifen medication and should use barrier or other non hormonal contraceptive methods if sexually active.
It is not known whether tamoxifen is excreted into breast milk. Therefore, tamoxifen treatment is contraindicated during breast-feeding. Tamoxifen inhibits lactation in humans and no rebound lactation was observed after completion of therapy.
No studies on the effects of the ability to drive and use machines have been performed.
Since visual disturbances and light-headedness have been observed commonly with the use of tamoxifen, caution is advised when driving or using machines. The amount of alcohol in this product may impair the ability to drive or use machines.
Unless specified, the following frequency categories were calculated from the number of adverse events reported in a large phase III study conducted in 9366 postmenopausal women patients with operable breast cancer treated for 5 years and unless specified, no account was taken of the frequency within the comparative treatment group or whether the investigator considered it to be related to study medication.
The frequencies of adverse events are ranked according to the following: very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1,000 to <1/100), rare (>1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Neoplasms benign, malignant and unspecified
Common: Uterine fibroids Uncommon: Endometrial cancer
Rare: Uterine sarcoma (mostly malignant mixed Mullerian tumours)a, tumour
Blood and lymphatic system disorders Common: Anaemia
Uncommon: Temporary thrombocytopenia (usually 80,00-90,000 per cu mm but occasionally lower), leukopenia (see sections 4.4 and 4.5)
Rare: Temporary reductions in blood count such as neutropeniaa (sometimes severe), agranulocytosisa Very Rare: Pancytopenia
Immune system disorders Common: Hypersensitivity reactions
Metabolism and nutrition disorders Very common: Fluid retention
Uncommon: Hypercalcaemia (in patients with bony metastases) on initiation of therapy (see section 4.4)
Very rare: Severe hypertriglyceridemia which may be partly combined with pancreatitis
Very Common: Depression (it is not known whether this is related to tamoxifen treatment or to other factors but depression is very common in women with breast cancer, see section 4.4)
Nervous system disorders
Common: Light-headedness, headache, cerebral ischaemic events, sensory disturbances (including paraestheia and dysgeusia)
Rare: Optic neuritis
Common: Cataracts and /or retinopathy that are only partly reversible. The risk for cataracts increases with the duration of tamoxifen treatment Uncommon: Visual disturbances
Rare: Corneal changes including optic neuropathya that is only partly reversible. In a small number of cases, blindness has occurred.
Very common: Hot flushes
Common: Thromboembolic events, including deep vein thrombosis, microvascular thrombosis and pulmonary embolism. The risk increases when tamoxifen is used in combination with cytotoxic agents (see sections 4.4 and 4.5)
Respiratory, thoracic and mediastinal disorders
Uncommon: Interstitial pneumonitis
Very common: Nausea
Common: Vomiting, diarrhoea and constipation Uncommon: Pancreatitis
Common: Changes in liver enzyme levels, fatty liver Uncommon: Cirrhosis of the liver
Rare: Hepatitis and cholestasisa, hepatic failurea, hepatocellular injurya and hepatic necrosisa. Some cases of more severe liver abnormalities have proved fatal
Skin and subcutaneous tissue disorders
Very common: Skin rash Common: Alopecia
Rare: Angioedema, Stevens-Johnson-syndromea, cutaneous vasculitisa, bullous pemphigoida or erythema multiformea Very rare: Cutaneous lupus erythematosusb
Musculoskeletal and connective tissue disorders
Common: Leg cramp, myalgia
Reproductive system and breast disorders
Very common: Vaginal discharge, vaginal bleeding
Common: Pruritus vulvae, endometrial changes (including hyperplasia and
Rare: Suppression of menstruation, cystic ovarian swellingsa, endometriosis and vaginal polyps
Congenital, familial and genetic disorders
Very rare: Porphyria cutanea tardab
General disorders and administration site conditions
Very common: Fatigue Common: Bone and tumour pain
Common: Elevated triglycerides, in some cases with pancreatitis
a This adverse drug reaction was not reported in the tamoxifen arm (n= 3094) of the above study; however, it has been reported in other trials or from other sources. The frequency has been calculated using the upper limit of the 95% confidence interval for the point estimate (based on 3/X, where X represents the total sample size e.g. 3094). This is calculated as 3/3094 which equates to a frequency category of ‘rare’.
b The event was not observed in other major clinical studies. The frequency has been calculated using the upper limit of the 95% confidence interval for the point estimate (based on 3/X, where X represents the total sample size of 13,357 patients in the major clinical studies). This is calculated as 3/13,357 which equates to a frequency category of ‘very rare’.
When undesirable events are severe it may be possible to control them by a simple reduction of dosage without loss of control of the disease. If undesirable events do not respond to this measure, it may be necessary to cease treatment.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professional are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard
At doses of 160mg/m daily and higher, changes in ECG (QT-prolongation) and at doses of 300 mg/m2 daily, neurotoxicity (tremor, hyperreflexia, gait disorders, and dizziness) occurred.
Overdosage of tamoxifen will increase the anti-oestrogenic effects. There is no specific antidote to overdosage and treatment should therefore be symptomatic.
Pharmacotherapeutic group: Hormone antagonists and related agents ATC Code: L02B A01
Tamoxifen is a non-steroidal anti-oestrogen and inhibits the effects of endogenous oestrogen, probably by binding with oestrogen receptors. Tamoxifen competes for the binding sites with estradiol and by occupying the receptor reduces the amount of receptor available for endogenous estradiol. Tamoxifen also prevents the normal feedback inhibition of oestrogen synthesis in the hypothalamus and in the pituitary.
Tamoxifen decreases cell division in oestrogen-dependent tissues. In metastatic breast cancer, partial or complete remissions were observed in 50-60% of cases, particularly in bone and soft tissue metastases if oestrogen-receptors were found in the tumour. In cases of negative hormone-receptor status, particularly of the metastases only approx. 10% showed objective remissions. Women with oestrogen receptor- positive tumours or tumours with unknown receptor status who received adjuvant treatment with tamoxifen experienced significantly less tumour recurrences and had a higher 10-year survival rate. The effect was greater after 5 years of adjuvant treatment compared with 1-2 years of treatment. The benefit appears to be independent of age, menopausal status, daily tamoxifen dose and additional chemotherapy.
In postmenopausal women, tamoxifen has no effect on the plasma concentrations of oestrogens but reduces the concentrations of LH-, FSH-, and prolactin, however within the normal range. Additionally tamoxifen has been reported to lead to maintenance of bone mineral density in postmenopausal women.
In premenopausal women, tamoxifen can increase the concentrations of oestrogens and prostagens but they will return to predose levels after discontinuation of the treatment.
In the clinical situation, it is recognised that tamoxifen leads to reduction in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10 - 20%. Tamoxifen increases steroid-and thyroxine-binding proteins and can thus affect the concentrations of cortisol and thyroid hormones. Additionally, tamoxifen reduces the plasma concentrations of antithrombin III
CYP2D6 polymorphism status may be associated with variability in clinical response to tamoxifen. The poor metaboliser status may be associated with reduced response. The consequences of the findings for the treatment of CYP2D6 poor metabolisers have not been fully elucidated (see sections 4.4, 4.5 and 5.2).
Available clinical data suggest that patients, who are homozygote for nonfunctional CYP2D6 alleles, may experience reduced effect of tamoxifen in the treatment of breast cancer.
The available studies have mainly been performed in postmenopausal women (see sections 4.4 and 5.2).
After oral administration tamoxifen is well-absorbed achieving maximum serum concentrations within 4 - 7 hours and is extensively metabolised.
Tamoxifen concentrations have been observed in lung, liver, adrenals, kidney, pancreas, uterus and mammary tissues.
Tamoxifen is highly protein bound to serum albumin (>99%). Metabolism is by hydroxylation, demethylation and conjugation, giving rise to several metabolites which have a similar pharmacological profile to the parent compound and thus contribute to the therapeutic effect. After four weeks of daily therapy, it was observed that steady state serum levels were achieved and an elimination half-life of seven days was calculated whereas that for N-desmethyltamoxifen, the principal circulating metabolite, is 14 days.
Elimination occurs, chiefly as conjugates with practically no unchanged drug, principally through the faeces and to a lesser extent through the kidneys.
Tamoxifen is metabolised mainly via CYP3A4 to N-desmethyl-tamoxifen, which is further metabolised by CYP2D6 to another active metabolite endoxifen. In patients who lack the enzyme CYP2D6 endoxifen concentrations are approximately 75% lower than in patients with normal CYP2D6 activity. Administration of strong CYP2D6 inhibitors reduces endoxifen circulating levels to a similar extent.
Although reproductive toxicology studies in rats, rabbits and monkeys have shown no teratogenic potential, tamoxifen was associated in rodent models of foetal reproductive tract development with changes similar to those caused by estradiol, ethynylestradiol, clomifene and diethylstilbestrol (DES). The clinical relevance of these changes is unknown. However some of them, especially vaginal adenosis, are similar to those seen in young women who were exposed to DES in utero (see section 4.6).
Tamoxifen was not mutagenic in a range if in vitro and in vivo mutagenicity tests. Investigations in different in vivo and in vitro systems have shown that tamoxifen has a genotoxic potential following hepatic activation. Gonadal tumours in mice and liver tumours in rats receiving tamoxifen have been reported in long-term studies. The clinical relevance of these findings has not been established.
Propylene glycol (E1520)
Sorbitol solution (non-crystallising) (E420)
Natural aniseed flavouring A05 (flavouring preparations, isopropyl alcohol, water)
Liquorice flavouring L03 (flavouring preparations, natural flavouring substances, artificial flavouring substances, propylene glycol (E1520), isopropyl alcohol)
Shelf life of the medicinal product as packaged for sale : 2 years. Shelf life after first opening the container: 3 months
Do not store above 25°C. Do not refrigerate or freeze. Store in the original package in order to protect from light.
Bottle: Amber (Type III) glass
Closure: HDPE, polyethylene wadded, tamper evident, child resistant
Pack: 150ml oral solution
No special requirements.
Rosemont Pharmaceuticals Ltd
Yorkdale Industrial Park
Date of first authorisation: 16 August 1999 Date of last renewal: 27 November 2004